Effect of PreforPro® on Urinary and Vaginal Health
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This study will investigate the effects of PreforPro® (prebiotic and bacteriophages
(LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae, greater > 6.7 X 107
PFU/gram) on bacterial vaginosis.
Phase:
Phase 3
Details
Lead Sponsor:
Jeremy Burton
Collaborators:
Deerland Enzymes Lawson Health Research Institute St. Joseph's Health Care London